• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. Aggregation dynamics, structure, and mechanical properties of bigels
  L. Di Michele,D. Fiocco,F. Varrato,E. Eiser,G. Foffi Soft Matter, 2014,10, 3633-3648
• 4. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 5. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331

Comprehensive Overview of 1-(3-methylcyclobutyl)methanamine (CAS No. 34577-92-9): Properties, Applications, and Industry Insights

1-(3-methylcyclobutyl)methanamine (CAS No. 34577-92-9) is a specialized organic compound with a unique cyclobutyl structure, attracting significant interest in pharmaceutical and agrochemical research. This amine derivative, characterized by its 3-methylcyclobutyl backbone, serves as a versatile building block in synthetic chemistry. Its molecular formula, C₆H₁₃N, and moderate lipophilicity make it valuable for designing bioactive molecules, particularly in drug discovery targeting CNS disorders and metabolic diseases—a trending focus in 2024’s AI-driven drug development pipelines.

The compound’s structural rigidity, imparted by the cyclobutane ring, enhances binding affinity to specific biological targets, a feature leveraged in small-molecule therapeutics. Recent studies highlight its potential in modulating G-protein-coupled receptors (GPCRs), aligning with industry demand for precision medicine solutions. Researchers frequently search for "CAS 34577-92-9 supplier" or "1-(3-methylcyclobutyl)methanamine synthesis protocol," reflecting its niche yet growing commercial relevance. Analytical data (e.g., NMR, HPLC) confirm >98% purity in optimized synthetic routes, a critical parameter for high-throughput screening applications.

Environmental and regulatory considerations are paramount in 2024. 1-(3-methylcyclobutyl)methanamine complies with REACH and TSCA frameworks, with biodegradation studies showing minimal ecotoxicity—addressing green chemistry concerns. Its stability under ambient conditions (decomposition >200°C) facilitates safe storage, a frequent query among logistics professionals. The compound’s low vapor pressure further reduces occupational exposure risks, a hotspot in ESG-compliant manufacturing discussions.

Innovative applications include its role as a chiral auxiliary in asymmetric catalysis, a technique gaining traction for cost-effective API production. Patent analyses reveal 18% annual growth in filings referencing this amine since 2021, particularly in neurodegenerative disease research. Computational chemists increasingly model its conformational dynamics using AI-based molecular docking tools, correlating with Google Trends’ 70% rise in searches for "machine learning in chemical design."

Supply chain analytics indicate Asia-Pacific as the dominant producer (62% market share), with custom synthesis services driving demand. Quality benchmarks emphasize residual solvent control (<50 ppm), a key differentiator for GMP-grade suppliers. The compound’s scalable production via reductive amination—often queried in process chemistry forums—exemplifies modern continuous flow optimization strategies.

Future prospects tie to bioisostere development, where its sp3-rich framework replaces flat aromatics in fragment-based drug design. Collaborations between academia and CDMOs aim to reduce synthesis costs by 30% through catalytic hydrogenation innovations—a topic with 1,200+ monthly searches on research databases. As structural diversity remains a priority in combinatorial chemistry, 34577-92-9 exemplifies how niche intermediates enable next-gen pharmacophores.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)